SCHEMBL6609154

SCHEMBL6609154

CNC(=O)c1ccc(-c2cc[c]cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
MKNK1 Q9BUB5 1/20 0.53
MKNK2 Q9HBH9 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
HPGD P15428 1/20 0.52
TSHR P16473 1/20 0.52
HTT P42858 1/20 0.52
PLK1 P53350 8/20 0.50
CA2 P00918 1/20 0.47
CRBN Q96SW2 1/20 0.46
MMP13 P45452 1/20 0.46
HDAC4 P56524 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
MAPT P10636 1/20 0.42
HDAC1 Q13547 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19403 0.87 HDAC8 (0.58) HDAC6HDAC2HDAC8MKNK1MKNK2
SCHEMBL16198923 0.87 HDAC6 (0.70) HDAC6HDAC2HDAC8MKNK1MKNK2
SCHEMBL14115137 0.87 HDAC6 (0.70) HDAC6HDAC2HDAC8MKNK1MKNK2
SCHEMBL8496406 0.82 HDAC6 (0.60) HDAC6HDAC2HDAC8CA2HDAC4
SCHEMBL250247 0.80 HDAC6 (0.80) HDAC6HDAC2HDAC8MKNK1MKNK2
SCHEMBL2026287 0.79 NPC1 (0.67) HDAC6HDAC2HDAC8MKNK1MKNK2
SCHEMBL21018210 0.79 HDAC6 (0.59) HDAC6HDAC2HDAC8MKNK1MKNK2
SCHEMBL16574182 0.79 MMP13 (0.69) HDAC6HDAC2HDAC8MKNK1MKNK2
SCHEMBL14676072 0.79 HDAC2 (0.59) HDAC6HDAC2HDAC8MKNK1MKNK2
SCHEMBL18821524 0.79 SMN1; SMN2 (0.59) HDAC6HDAC2HDAC8MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US claimed
EP-1423386-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP claimed
WO-2003022842-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-20 WO claimed
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed
EP-1423386-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP disclosed
WO-2003022842-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors TNF, MMP9, MMP1 HDAC6 1429/4885HDAC2 836/4885HDAC8 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.